Related Experiment Videos
Vascular endothelial growth factor as a target for anticancer therapy
1Genentech, Inc., South San Francisco, California 94080, USA. nf@gene.com
The Oncologist
|June 5, 2004
Summary
Vascular endothelial growth factor (VEGF) drives tumor growth and spread. Inhibiting VEGF, a key factor in tumor angiogenesis, shows promise for enhancing cancer therapies like chemotherapy and radiotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Tumor vascularization is crucial for growth and metastasis.
- Vascular endothelial growth factor (VEGF) is a primary regulator of angiogenesis.
- VEGF overexpression correlates with poor prognosis in some cancers.
Purpose of the Study:
- To investigate VEGF as a therapeutic target in cancer.
- To evaluate the potential of inhibiting tumor angiogenesis.
- To explore combination strategies for cancer treatment.
Main Methods:
- Review of current research on VEGF and angiogenesis.
- Analysis of preclinical and clinical data for VEGF inhibitors.
- Assessment of combination therapy effectiveness.
Main Results:
- VEGF plays a critical role in tumor angiogenesis.
- Inhibiting VEGF can enhance chemotherapy and radiotherapy efficacy.
- Bevacizumab, an anti-VEGF antibody, is advanced in clinical trials with promising results.
Conclusions:
- Targeting VEGF offers a promising strategy for cancer treatment.
- Combination therapy with VEGF inhibitors and traditional treatments may improve outcomes.
- Bevacizumab represents a leading therapeutic candidate in this approach.